The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

Cancer Cell

Volumn 3, Issue 2, 2003, Pages 185-197

  Rosenwald, Andreas ^a   Wright, George ^a   Wiestner, Adrian ^a   Chan, Wing C ^a,d   Connors, Joseph M ^a,j   Campo, Elias ^a,c   Gascoyne, Randy D ^a,j   Grogan, Thomas M ^a,f,i   Muller Hermelink, H Konrad ^a,k   Smeland, Erlend B ^a,l   Chiorazzi, Michael ^a   Giltnane, Jena M ^a   Hurt, Elaine M ^a   Zhao, Hong ^a   Averett, Lauren ^a   Henrickson, Sarah ^a   Yang, Liming ^a,b   Powell, John ^a,b   Wilson, Wyndham H ^a   Jaffe, Elaine S ^a   Simon, Richard ^a   Klausner, Richard D ^a   Montserrat, Emilio ^a,c   Bosch, Francesc ^a,c   Greiner, Timothy C ^a,d   Weisenburger, Dennis D ^a,d   Sanger, Warren G ^a,d   Dave, Bhavana J ^a,d   Lynch, James C ^a,e   Vose, Julie ^a,e   Armitage, James O ^a,e   Fisher, Richard I ^a,h,i   Miller, Thomas P ^a,f,i   LeBlanc, Michael ^a,g,i   Ott, German ^a,k   Kvaloy, Stein ^a,l   Holte, Harald ^a,l   Delabie, Jan ^a,l   Staudt, Louis M ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

ⁱ Southwest Oncology Group   (Canada)

^j BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MESSENGER RNA; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN P16INK4A; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RNA; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE LOCUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MOLECULAR DYNAMICS; ONCOGENE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ADULT; AGED; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR GENE; UNTRANSLATED REGION;

ADP-RIBOSYLATION FACTORS; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UNTRANSLATED REGIONS;

EID: 0013224058     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00028-X     Document Type: Article

References (57)

1. Alizadeh A., Eisen M., Davis R.E., Ma C., Sabet H., Tran T., Powell J., Yang L., Marti G., Moore T., et al. The Lymphochip. A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes Cold Spring Harb. Symp. Quant. Biol. 64:1999;71-78.
2. Argatoff L.H., Connors J.M., Klasa R.J., Horsman D.E., Gascoyne R.D. Mantle cell lymphoma. a clinicopathologic study of 80 cases Blood. 89:1997;2067-2078.
3. Barista I., Romaguera J.E., Cabanillas F. Mantle-cell lymphoma. Lancet Oncol. 2:2001;141-148.
4. Bayes T. An essay towards solving a problem in the doctrine of chances. Phil Trans Roy Soc London. 53:1763;370.
5. Bea S., Ribas M., Hernandez J.M., Bosch F., Pinyol M., Hernandez L., Garcia J.L., Flores T., Gonzalez M., Lopez-Guillermo A., et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood. 93:1999;4365-4374.
6. Bea S., Tort F., Pinyol M., Puig X., Hernandez L., Hernandez S., Fernandez P.L., van Lohuizen M., Colomer D., Campo E. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 61:2001;2409-2412.
7. Bentz M., Plesch A., Bullinger L., Stilgenbauer S., Ott G., Muller-Hermelink H.K., Baudis M., Barth T.F., Moller P., Lichter P., Dohner H. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 27:2000;285-294.
8. Bijwaard K.E., Aguilera N.S., Monczak Y., Trudel M., Taubenberger J.K., Lichy J.H. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression. utility in the diagnosis of mantle cell lymphoma Clin. Chem. 47:2001;195-201.
9. Bosch F., Jares P., Campo E., Lopez-Guillermo A., Piris M.A., Villamor N., Tassies D., Jaffe E.S., Montserrat E., Rozman C., et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders. a highly specific marker of mantle cell lymphoma Blood. 84:1994;2726-2732.
10. Bosch F., Lopez-Guillermo A., Campo E., Ribera J.M., Conde E., Piris M.A., Vallespi T., Woessner S., Montserrat E. Mantle cell lymphoma. presenting features, response to therapy, and prognostic factors Cancer. 82:1998;567-575.
11. Campo E., Raffeld M., Jaffe E.S. Mantle-cell lymphoma. Semin. Hematol. 36:1999;115-127.
12. de Boer C.J., van Krieken J.H., Kluin-Nelemans H.C., Kluin P.M., Schuuring E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene. 10:1995;1833-1840.
13. Dreyling M.H., Bullinger L., Ott G., Stilgenbauer S., Muller-Hermelink H.K., Bentz M., Hiddemann W., Dohner H. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res. 57:1997;4608-4614.
14. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:1999;2658-2669.
15. Goff L.K., Neat M.J., Crawley C.R., Jones L., Jones E., Lister T.A., Gupta R.K. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br. J. Haematol. 111:2000;618-625.
16. Gopal A.K., Rajendran J.G., Petersdorf S.H., Maloney D.G., Eary J.F., Wood B.L., Gooley T.A., Bush S.A., Durack L.D., Martin P.J., et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 99:2002;3158-3162.
17. Greiner T.C., Moynihan M.J., Chan W.C., Lytle D.M., Pedersen A., Anderson J.R., Weisenburger D.D. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 87:1996;4302-4310.
18. Hernandez L., Fest T., Cazorla M., Teruya-Feldstein J., Bosch F., Peinado M.A., Piris M.A., Montserrat E., Cardesa A., Jaffe E.S., et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 87:1996;3351-3359.
19. Hills M. Allocation rules and error rates. J. Royal. Statis. Soc. B. 28:1966;1-31.
20. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 397:1999;164-168.
21. Jaffe E.S., Harris N.L., Diebold J., Muller-Hermelink H.K. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am. J. Clin. Pathol. 111:1999;S8-S12.
22. Jaffe, E.S., Harris, N.L., Stein, H., and Vardiman, J.W. (2001). Tumours of Haematopoietic and Lymphoid Tissues (Lyon, IARC Press).
23. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91:1997;649-659.
24. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA. 95:1998;8292-8297.
25. Karlseder J., Broccoli D., Dai Y., Hardy S., de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1999;1321-1325.
26. Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia- telangiectasia. Cell. 71:1992;587-597.
27. Labuhn M., Jones G., Speel E.J., Maier D., Zweifel C., Gratzl O., Van Meir E.G., Hegi M.E., Merlo A. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Oncogene. 20:2001;1103-1109.
28. Lardelli P., Bookman M.A., Sundeen J., Longo D.L., Jaffe E.S. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am. J. Surg. Pathol. 14:1990;752-763.
29. Lebwohl D.E., Muise-Helmericks R., Sepp-Lorenzino L., Serve S., Timaul M., Bol R., Borgen P., Rosen N. A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene. 9:1994;1925-1929.
30. Leonard J.P., Schattner E.J., Coleman M. Biology and management of mantle cell lymphoma. Curr. Opin. Oncol. 13:2001;342-347.
31. Lin S., Wang W., Wilson G.M., Yang X., Brewer G., Holbrook N.J., Gorospe M. Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover. Mol. Cell. Biol. 20:2000;7903-7913.
32. Louie D.C., Offit K., Jaslow R., Parsa N.Z., Murty V.V., Schluger A., Chaganti R.S. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood. 86:1995;2892-2899.
33. Perkins E.J., Nair A., Cowley D.O., Van Dyke T., Chang Y., Ramsden D.A. Sensing of intermediates in V(D)J recombination by ATM. Genes Dev. 16:2002;159-164.
34. Pinyol M., Hernandez L., Cazorla M., Balbin M., Jares P., Fernandez P.L., Montserrat E., Cardesa A., Lopez-Otin C., Campo E. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 89:1997;272-280.
35. Pinyol M., Cobo F., Bea S., Jares P., Nayach I., Fernandez P.L., Montserrat E., Cardesa A., Campo E. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood. 91:1998;2977-2984.
36. Pinyol M., Hernandez L., Martinez A., Cobo F., Hernandez S., Bea S., Lopez-Guillermo A., Nayach I., Palacin A., Nadal A., et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am. J. Pathol. 156:2000;1987-1996.
37. Quintanilla-Martinez L., Davies-Hill T., Fend F., Calzada-Wack J., Sorbara L., Campo E., Jaffe E.S., Raffeld M. Sequestration of p27kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphomas (MCL). implication for pathogenesis Blood. in press: 2003.
38. Radmacher M.D., McShane L.M., Simon R. A paradigm for class prediction using gene expression profiles. J. Comput. Biol. 9:2002;505-511.
39. Raffeld M., Jaffe E.S. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 78:1991;259-263.
40. Randle D.H., Zindy F., Sherr C.J., Roussel M.F. Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc. Natl. Acad. Sci. USA. 98:2001;9654-9659.
41. Raty R., Franssila K., Joensuu H., Teerenhovi L., Elonen E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur. J. Haematol. 69:2002;11-20.
42. Rimokh R., Berger F., Bastard C., Klein B., French M., Archimbaud E., Rouault J.P., Santa Lucia B., Duret L., Vuillaume M., et al. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle- cell lymphomas and t(11q13)-associated leukemias. Blood. 83:1994;3689-3696.
43. Rosenberg C.L., Wong E., Petty E.M., Bale A.E., Tsujimoto Y., Harris N.L., Arnold A. PRAD1, a candidate BCL1 oncogene. mapping and expression in centrocytic lymphoma Proc. Natl. Acad. Sci. USA. 88:1991;9638-9642.
44. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., Gascoyne R.D., Muller-Hermelink H.K., Smeland E.B., Giltnane J.M., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:2002;1937-1947.
45. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., Lowe S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 109:2002;335-346.
46. Seto M., Yamamoto K., Iida S., Akao Y., Utsumi K.R., Kubonishi I., Miyoshi I., Ohtsuki T., Yawata Y., Namba M., et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene. 7:1992;1401-1406.
47. Shaffer A.L., Rosenwald A., Hurt E.M., Giltnane J.M., Lam L.T., Pickeral O.K., Staudt L.M. Signatures of the immune response. Immunity. 15:2001;375-385.
48. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2:2002;103-112.
49. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
50. Sherr C.J., Roberts J.M. CDK inhibitors. positive and negative regulators of G1-phase progression Genes Dev. 13:1999;1501-1512.
51. Swerdlow S.H., Williams M.E. From centrocytic to mantle cell lymphoma. a clinicopathologic and molecular review of 3 decades Hum. Pathol. 33:2002;7-20.
52. TNHLCP A (The Non-Hodgkin's Lymphoma Classification Project.) clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 89:1997;3909-3918.
53. Velders G.A., Kluin-Nelemans J.C., De Boer C.J., Hermans J., Noordijk E.M., Schuuring E., Kramer M.H., Van Deijk W.A., Rahder J.B., Kluin P.M., Van Krieken J.H. Mantle-cell lymphoma. a population-based clinical study J. Clin. Oncol. 14:1996;1269-1274.
54. Weisenburger D.D., Armitage J.O. Mantle cell lymphoma-an entity comes of age. Blood. 87:1996;4483-4494.
55. Withers D.A., Harvey R.C., Faust J.B., Melnyk O., Carey K., Meeker T.C. Characterization of a candidate bcl-1 gene. Mol. Cell. Biol. 11:1991;4846-4853.
56. Xiong Y., Connolly T., Futcher B., Beach D. Human D-type cyclin. Cell. 65:1991;691-699.
57. Yatabe Y., Suzuki R., Tobinai K., Matsuno Y., Ichinohasama R., Okamoto M., Yamaguchi M., Tamaru J., Uike N., Hashimoto Y., et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma. a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma Blood. 95:2000;2253-2261.